1. Home
  2. SPCB vs CTSO Comparison

SPCB vs CTSO Comparison

Compare SPCB & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SuperCom Ltd. (Israel)

SPCB

SuperCom Ltd. (Israel)

HOLD

Current Price

$8.48

Market Cap

45.3M

Sector

Technology

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.68

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPCB
CTSO
Founded
1988
1997
Country
Israel
United States
Employees
N/A
N/A
Industry
Semiconductors
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.3M
45.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SPCB
CTSO
Price
$8.48
$0.68
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$18.00
$5.38
AVG Volume (30 Days)
50.7K
139.8K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.84
N/A
Revenue
$26,739,000.00
$36,979,520.00
Revenue This Year
N/A
$7.26
Revenue Next Year
$27.13
$9.78
P/E Ratio
$10.34
N/A
Revenue Growth
N/A
23.89
52 Week Low
$5.06
$0.60
52 Week High
$18.95
$1.61

Technical Indicators

Market Signals
Indicator
SPCB
CTSO
Relative Strength Index (RSI) 39.26 49.64
Support Level $8.98 $0.62
Resistance Level $9.47 $0.68
Average True Range (ATR) 0.49 0.05
MACD -0.08 0.00
Stochastic Oscillator 11.11 48.48

Price Performance

Historical Comparison
SPCB
CTSO

About SPCB SuperCom Ltd. (Israel)

SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: